DIRS.INFO The most relevant business & tech news

Still, Eli Lilly and Novo Nordisk appear to be making some encouraging progress. Eli Lilly wasn't the only weight loss drug producer to see positive supply developments in the last week. Novo Holdings, which owns almost 77% of the voting shares in Novo Nordisk, said Monday it will acquire drug manufacturer Catalent in a $16.5 billion deal. Novo Nordisk will then buy three of Catalent's manufacturing plants from Novo Holdings for $11 billion. Tema in November launched an ETF whose key holdings include companies benefiting from the hype around weight loss drugs.

Persons: Eli Lilly, Anat Ashkenazi, Incretin, Eli Lilly's, Ashkenazi, Eli Lilly wasn't, Yuri Khodjamirian, Danish drugmaker Organizations: Novo Nordisk, Holdings, Wegovy, Novo Holdings, CNBC, Tema, Nordisk, Reuters Locations: North Carolina, Novo, Tema, Brussels, Danish, U.S

☆ Stocks making the biggest moves midday: Nvidia, Boeing, Snap, Tyson Foods and more
▼ + stars: | 2024-02-05 | by ( Brian Evans | ) www.cnbc.com time to read: +3 min

McDonald's posted adjusted earnings of $2.95 per share on $6.41 billion in revenue. Analysts had expected earnings of $2.82 per share and $6.45 billion in revenue, according to LSEG, formerly known as Refinitiv. Analysts polled by FactSet forecast earnings of $2.30 per share on $8.9 billion in revenue for the fourth quarter. The company posted adjusted earnings of 69 cents per share on revenue of $13.32 billion. Caterpillar reported adjusted earnings of $5.23 per share on revenue of $17.07 billion.

Persons: Goldman Sachs, McDonald's, Eli Lilly, Jim Umpleby, Estée Lauder —, Dali Rajic, —, Macheel, Jesse Pound, Hakyung Kim, Alex Harring, Michelle Fox, Sarah Min, Darla Mercado Organizations: Nvidia, Novo Nordisk —, Novo Holdings, Novo Nordisk, Management, U.S . Food, Boeing —, Boeing, Tyson, Caterpillar, Air Products, Chemicals, Reuters Locations: Novo, U.S

☆ The market is seeing red. But here's why a few of our portfolio stocks are standing out
▼ + stars: | 2024-02-05 | by ( Jeff Marks | ) www.cnbc.com time to read: +5 min

Every weekday the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable update of the trading day, just in time for the last hour on Wall Street. "Microsoft is the one to buy first on weakness due to the quality of last week's quarter and outlook," Jim Cramer said Monday. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, Jerome Powell's, Estee Lauder, Jim, Cramer, Eli Lilly, Lilly, Linde, Jim Cramer's, Brendan McDermid Organizations: CNBC, Federal, Nvidia, Apple, Microsoft, Sector, Technology, Semiconductor, Novo Nordisk, Air Products, Chemicals, Products, Linde, ., Vertex Pharmaceuticals, Simon Property Group, NXP Semiconductors, Club, GE Healthcare, DuPont, Carrier Global, Jacobs Solutions, Ford, Jim Cramer's Charitable, Traders, New York Stock Exchange Locations: We're, Novo, China, New York City, U.S

☆ Novo Nordisk parent to buy Catalent for $16.5 billion to expand Wegovy supply
▼ + stars: | 2024-02-05 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Novo Nordisk will then buy three of Catalent's manufacturing sites from Novo Holdings for $11 billion. Novo Holdings owns almost 77% of the voting shares in Novo Nordisk. Novo Nordisk and Novo Holdings said they expect the acquisition of the plants and the broader deal to buy Catalent to close at the end of 2024. Novo Nordisk added that it expects its purchase to gradually help increase its filling capacity beginning in 2026. Under the terms of the deal, Novo Holdings will buy Catalent for $63.50 a share in cash, a premium of 16.5% to Catalent's closing price on Friday.

Persons: Catalent, Eli Lilly Organizations: Nordisk, Novo Holdings, Novo Nordisk's Wegovy, Novo Nordisk, Novo, Elliott Investment Management, U.S ., Reuters, CNBC PRO Locations: Novo, Italy, Belgium, Bloomington , Indiana, Denmark, France, U.S, Brussels

☆ Here are Jim Cramer's rapid-fire takes on 5 stocks in the news Monday
▼ + stars: | 2024-02-05 | by ( Paulina Likos | ) www.cnbc.com time to read: +1 min

Jim Cramer said this deal is Novo's way to "get more product" and addresses the "tremendous shortage" of these high-demand drugs. Shares of Eli Lilly , a stock in the CNBC Investing Club 's portfolio, were also up more than 4% ahead of Tuesday's earnings. Snap – The social media firm laid off 10% of its workforce ahead of Tuesday's earnings. Jim pointed out that Club name Starbucks (SBUX) has also been experiencing the same thing. Jim said buy McDonald's stock on weakness.

Persons: Jim Cramer, Eli Lilly, Lilly, Cramer, Cigna –, Cantor Fitzgerald, Jim Organizations: Nordisk, Catalent, CNBC, Microsoft, RBC Capital, Humana, Starbucks, Mattel –, JPMorgan, Vision, Apple Locations: Danish, Israel

☆ Comeback stocks: These names have jumped to start 2024 after falling last year
▼ + stars: | 2024-02-05 | by ( Hakyung Kim | ) www.cnbc.com time to read: +3 min

The Russell 1000 , which tracks the top 1,000 largest companies — large- and mid-cap names — is up about 3% in 2024. With this in mind, CNBC Pro screened for the stocks making a comeback in 2024. However, the consensus price target is just 4.6% from its current levels — putting into question whether there's more room for upside. Just 35.7% of analysts are bullish on the shares, and the average price target implies shares can grow just 4.3%. Sarepta Therapeutics has soared 27.4% this year — and it could jump 20.1% more according to its consensus price target, per LSEG.

Persons: Russell, they're, Merck's, Sarepta Organizations: CNBC Pro, Pharmaceutical, Merck, Verizon, Barclays, VZ, LSEG, Novo Nordisk, Sarepta Therapeutics Locations: Novo

☆ Want to cash in on the weight-loss drug boom? Morgan Stanley names 4 global stocks
▼ + stars: | 2024-02-01 | by ( Amala Balakrishner | ) www.cnbc.com time to read: +4 min

Under-the-radar stock picks Morgan Stanley reckons the way to play the obesity theme in Asia is through names involved in GLP-1 drug development that "could find upside in burgeoning overseas markets." Calling it "top beneficiary as global demand for GLP-1 drugs significantly outpaces capacity," Morgan Stanley has an overweight rating on the stock. Morgan Stanley has an investment horizon of just over six months for WuXi AppTec and Innovent and over 12 months for Chugai and EBOS. Morgan Stanley's analysts estimate that worldwide sales of Orforglipron could hit $7 billion in 2023. Elsewhere, it sees opportunities for EBOS following the Australian government's approval for it to distribute obesity drugs.

Persons: Eli Lilly, Morgan, Sean Wu, Morgan Stanley's, Health Organization's, Morgan Stanley, Chugai, Goldman, EBOS, CNBC's Michael Bloom Organizations: Novo Nordisk, Health, WHO, BMI, WuXi AppTec, Australian, Hong Kong Stock Exchange, China Health Care, Goldman Sachs, Health Care Equity, Zealand ETF Locations: U.S, Asia, Asia Pacific, Australia, GLP, WuXi, China, Japan, New Zealand, Zealand

☆ Novo Nordisk beats earnings expectations as Wegovy, Ozempic demand soars
▼ + stars: | 2024-01-31 | by ( Elliot Smith | ) www.cnbc.com time to read: 1 min

Novo Nordisk, Europe's largest company by market capitalization, on Wednesday reported better-than-expected 2023 earnings, as sales of its wildly popular anti-obesity and diabetes drugs continued to soar. The maker of weight loss drug Wegovy and diabetes drug Ozempic reported an increase in sales of 31% in Danish kroner and 36% at constant exchange rates (CER) to 232.3 billion kroner ($33.71 billion). Full-year operating profit jumped by 37% in kroner and 44% at constant exchange rates to 102.6 billion kroner. The Danish pharmaceutical giant said it expects sales growth this year of between 18% and 26% in CER terms, as demand surges for Wegovy and Ozempic, which contain the same active ingredient. The 2023 results were fueled by strong performance in the company's diabetes and obesity care division, with obesity care in particular spiking by 154% at CER to 41.6 billion.

Persons: Ozempic Organizations: Novo Nordisk Locations: Europe's, Danish, CER

☆ Obesity drug supply-demand imbalance is working in Novo Nordisk's favor: Mizuho's Jared Holz
▼ + stars: | 2024-01-31 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailObesity drug supply-demand imbalance is working in Novo Nordisk's favor: Mizuho's Jared HolzJared Holz, Mizuho Securities, joins 'Fast Money' to talk demand in the obesity drug space and who is benefiting from the supply-demand imbalance.

Persons: Jared Holz Jared Holz Organizations: Obesity, Novo Nordisk's, Mizuho Securities Locations: Novo, Mizuho

☆ Here are Jim Cramer's rapid-fire takeaways on 6 stocks in the news Wednesday
▼ + stars: | 2024-01-31 | by ( Matthew J. Belvedere | ) www.cnbc.com time to read: +2 min

Jim said, "I don't know if [CEO] Carol Tome can keep the job." The fact is, he added, e-commerce is very strong and "she's not participating in it." Walmart — Founder Sam Walton liked the idea that people shouldn't have to own fractional shares, Jim said, praising the retailer's 3-for-1 stock split . "Very smart move by Walmart" to entice the individual investor with a smaller share price, Jim added. General Motors — Shares on Wednesday added to their 7.8% gain in the prior session on a strong quarter and 2024 guidance.

Persons: Jim, Carol Tome, Sam Walton, Mary Barra, Dave Calhoun didn't, Calhoun, Ozempic, Eli Lilly, Lilly, Tesla, Elon Organizations: Parcel Service, Walmart, General Motors, GM, CNBC, Club, Ford Motor, Boeing, Novo Nordisk — Locations: Delaware

☆ Novo Nordisk CEO on Q4 results, soaring demand for Wegovy and Ozempic
▼ + stars: | 2024-01-31 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailNovo Nordisk CEO on Q4 results, soaring demand for Wegovy and OzempicNovo Nordisk president and CEO Lars Fruergaard Jørgensen joins 'Squawk Box' to discuss the company's quarterly earnings results, which reported better-than-expected 2023 earnings, surging demand for Wegovy and Ozempic, and more.

Persons: Lars Fruergaard Jørgensen Organizations: Novo Nordisk, Ozempic Novo Nordisk

☆ Norway's giant wealth fund touts possibility of Novo Nordisk, Eli Lilly joining the trillion-dollar club
▼ + stars: | 2024-01-31 | by ( Sam Meredith | ) www.cnbc.com time to read: +1 min

A pharmacist displays boxes of Ozempic, a semaglutide injection drug used for treating type 2 diabetes made by Novo Nordisk, at Rock Canyon Pharmacy in Provo, Utah, U.S. March 29, 2023. Norway's giant wealth fund, the world's largest, touted the possibility that Danish drugmaker Novo Nordisk and U.S. rival Eli Lilly could be on course to become the first healthcare members of the trillion-dollar club. Novo Nordisk, Europe's largest firm by market capitalization, on Wednesday reported stronger-than-anticipated 2023 earnings, as sales of its hugely popular drug Wegovy continued to soar. The largest pharmaceutical company in the world by market value, Eli Lilly currently stands at roughly $612 billion. NBIM, the world's biggest single stock market investor, holds a 2.5% stake in Novo Nordisk and a 0.98% stake in Eli Lilly, according to LSEG data.

Persons: Eli Lilly, Wegovy, Gemma Game, Eli Lilly's Zepbound Organizations: Novo Nordisk, Pharmacy, Norges Bank Investment Management, Nordisk's Ozempic Locations: Provo , Utah, U.S, Danish, Europe's

☆ Obesity product competition is a 'win-win' for companies and society, Novo Nordisk CEO says
▼ + stars: | 2024-01-31 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailObesity product competition is a 'win-win' for companies and society, Novo Nordisk CEO saysNovo Nordisk CEO Lars Fruergaard Jørgensen speaks to CNBC following blockbuster earnings from Europe's largest company, driven by soaring demand for its obesity and diabetes drugs Wegovy and Ozempic.

Persons: Lars Fruergaard Jørgensen, Wegovy Organizations: Novo Nordisk, CNBC

☆ Cramer's rapid-fire look at six stocks in the news Wednesday
▼ + stars: | 2024-01-31 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailCramer's rapid-fire look at six stocks in the news WednesdayJim Cramer looks at what's going on a UPS, Walmart, GM, Boeing, Novo Nordisk and Tesla.

Persons: Jim Cramer Organizations: UPS, Walmart, GM, Boeing, Novo Nordisk, Tesla

STAVANGER (AP) — Norway’s oil fund reported the largest annual return in its history Tuesday, a performance led by U.S. technology companies and Danish pharmaceutical company Novo Nordisk, which makes the diabetes-turned-weight loss drug Ozempic. Norway’s Government Pension Fund Global, the world’s largest sovereign wealth fund, said it also benefited in 2023 from market excitement over the rapid adoption of artificial intelligence technology such as ChatGPT. The six largest contributors to the fund’s growth were the U.S technology companies Microsoft, Apple, NVIDIA, Meta, Amazon and Alphabet. Nova Nordisk also makes a higher dose version of the same medication that is sold as a weight loss drug under the brand name Wegovy. Political Cartoons View All 253 ImagesThe Government Pension Fund Global, known commonly as the Oil Fund, invests Norway's profits from oil and gas, and owns around 1.5% of all the companies listed globally.

Persons: Nicolai Tangen, Tesla, Ozempic Organizations: STAVANGER, Novo Nordisk, Fund, Oil, Microsoft, Apple, NVIDIA, Meta, Nova Nordisk, Nordisk, Government Pension Fund, Oil Fund Locations: U.S, Danish, Norway’s, Norway, Denmark

☆ We're calling up a health care stock from our Bullpen watch list, starting a new position
▼ + stars: | 2024-01-29 | by ( Jim Cramer | ) www.cnbc.com time to read: +7 min

Shortly after the opening bell, we're initiating a position in Abbott Laboratories (ABT), buying 275 shares at roughly $112 each. The way Abbott's stock has traded, it's acted like GLP-1s were a cure and people would no longer need these devices. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. If Jim has talked about a stock on CNBC TV, he waits 72 hours after issuing the trade alert before executing the trade.

Persons: Jim Cramer's, Abbott, Novo's, it's, Eli Lilly, we're, We're, Alinity, Abbott isn't, Jim Cramer, Jim Organizations: Abbott Laboratories, ABT, Jim Cramer's Charitable, Abbott, Novo Nordisk, Nutrition, JPMorgan, Pharmaceuticals, Core, GLP, Diagnostics, CNBC Locations: United States, LLY

☆ This week will make it clearer if the Fed will cut interest rates in March
▼ + stars: | 2024-01-28 | by ( Bryan Mena | ) edition.cnn.com time to read: +11 min

Washington, DC CNN —A slew of economic news this week will make it much clearer if the Federal Reserve will cut interest rates in March. The Labor Department is due to release four crucial assessments of America’s job market, gauging labor demand, wage growth, productivity and hiring. Wages and the Fed on Wednesday: The day after, the Labor Department releases its Employment Cost Index for the fourth quarter, a comprehensive measure of employers’ labor costs. The US Labor Department releases December data on job openings, quits, hires and layoffs. The US Labor Department releases its Employment Cost Index for the fourth quarter.

Persons: that’s, ”, Christian Scherrmann, Jerome Powell, ” Michael Feroli, “, ” Feroli, Powell, Alicia Wallace, Joe Brusuelas, Jerome Powell’s Organizations: CNN Business, Bell, DC CNN, Federal Reserve, Labor Department, DWS, Labor, Survey, Fed, Employers, PCE, Federal, Commerce Department, RSM, Whirlpool, Microsoft, UBS, HCA Healthcare, General Motors, Cleveland Cliffs, Mondelez International, JetBlue Airways, Global, US Labor Department, Board, National Bureau of Statistics, Novo Nordisk, Mastercard, Novartis, Boeing, ADP, Nasdaq, Nomura Holdings, Apple, Shell, Honeywell, Deutsche Bank, Clorox, Quest Diagnostics, United States Steel, Bank of England, P Global, Institute for Supply Management, Exxon Mobil, AbbVie, Regeneron Pharmaceuticals, University of Michigan Locations: Washington, Marathon, Cleveland, Chevron

☆ 10 of our stocks report earnings next week. Here's what we want to see from each
▼ + stars: | 2024-01-27 | by ( Zev Fima | ) www.cnbc.com time to read: +16 min

All three major averages posted gains for the third consecutive week, lifted by solid quarterly earnings and positive economic data. Earnings season ramps up next week, with five of the Super Six mega-cap stocks delivering results. Employment numbers are the most important economic data, with Friday's January nonfarm payrolls report carrying the most weight. The January ISM Manufacturing report on Thursday and December's factory orders report Friday are expected to show the sector still in contraction mode. But earnings and commentary this week from peer Sartorious made us encouraged about a return to growth in 2024.

Persons: nonfarm, December's, Sartorious, We've, Stanley Black, Decker, We're, We'd, Royal Philips, Crane, Woodward, ServisFirst, Cadence Bancorporation, CADE, Johnson, Phillips, Avery Dennison, Columbus McKinnon, Robinson, SIRI, Cardinal Health, Parker, DOV, Pitney Bowes, Ferrari N.V, CSW, COLM, W.W, Grainger, Dwight Co, Jim Cramer's, Jim Cramer, Jim, Tim Cook, Justin Sullivan Organizations: Gross, Procter, Gamble, Gillette, Super, Consumer, JPM Healthcare, Amazon, Microsoft, Honeywell, Aerospace, Solutions, Apple Watch, Masimo, Vision Pro, Franklin Resources, Resource Partners, Bank of Marin Bancorp, Bank7 Corp, Pacific Premier Bancorp Inc, Provident Financial Holdings, Dynex, Cliffs Inc, Nucor Corp, Whirlpool Corp, F5 Networks, Capital Southwest Corp, Harbors Investment Corp, Crane Co, Payne, Equity, Heartland Financial, Cadence, FinWise Bancorp, Five Star Bancorp, PotlatchDeltic Corporation, Sanmina Corporation, Pfizer, General Motors Corp, United Parcel Service, JetBlue Airways Corporation, Smith Corp, Marathon Petroleum Corp, HCA Healthcare, Oshkosh Corporation, SYSCO Corp, Danaher Corp, Johnson Controls, M.D.C . Holdings, Commvault Systems Inc, Hope Bancorp, Hubbell Incorporated, Malibu Boats, Polaris Industries, Inc, Camden National Corp, Cambridge Bancorp, Microsoft Corp, Starbucks Corp, Devices, Electronic Arts Inc, Juniper Networks, Stryker Corp, Lending, Canadian, Canadian Pacific Kansas City Limited, Mondelez, Chubb Corporation, Modine Manufacturing, Partners, Management, Hawaiian Holdings, Manhattan Associates, Unum Group, UNM, Axos, Enova, Boston Properties, Boeing Co, Novo Nordisk, Mastercard Inc, Roper Technologies, Boston Scientific Corporation, MarketAxess Holdings, Fisher, Aptiv PLC, Hess Corp, Nasdaq, United Microelectronics Corp, Rockwell Automation, Teva Pharmaceutical Industries, Ltd, Avery, Avery Dennison Corp, Extreme Networks, Otis Worldwide Corporation, OTIS, Columbus, Columbus McKinnon Corp, Central Pacific Financial Corp, Brinker International, Fortive Corporation, Qualcomm, Technology, Metlife, Hanover Insurance, Barn Holdings, CONMED Corporation, DLH Holdings Corp, Meritage Homes Corporation, Honeywell International, Eaton Corp, Altria, Royal Caribbean Cruises Ltd, Merck, Co, Enterprise Products Partners, Dorian LPG, SiriusXM Holdings, Cardinal, Hannifin Corporation, Allegheny Technologies Incorporated, Tractor Supply Company, Trane Technologies, Dover Corp, Huntington Ingalls Industries, Brunswick Corporation, Dickinson, Canada Goose Holdings, Kirby Corp, WEC Energy Group, WestRock Company, Allegro MicroSystems, Ball Corporation, Broadridge Financial, BrightSphere Investment Group, CMS Energy Corp, Lancaster Colony Corp, Rogers Communications Inc, Sanofi, Apple, Atlassian Corporation, United States Steel Corp, Corp, Adtalem Global, Homes, DXC Technology Company, Eastman Chemical Company, Gen, Post Holdings, America, Columbia Sportswear Company, Exxon Mobil Corp, Chevron Corporation, Myers Squibb Co, CIGNA Corp, Regeneron Pharmaceuticals, Charter Communications, AON, Cboe, Dwight, Banco Santander, Jim Cramer's Charitable, CNBC, Apple Vision, Getty Locations: China, East, United States, Europe, Cleveland, Alexandria, California, Corning, Canadian Pacific, Teradyne, TER, Novo, Hanover, PBI, Skechers U.S.A, Bristol, Chile

☆ LVMH shares jump 8% as earnings point to luxury sector resilience
▼ + stars: | 2024-01-26 | by ( Elliot Smith | ) www.cnbc.com time to read: +3 min

Bernard Arnault, Chairman and CEO of LVMH Moet Hennessy Louis Vuitton, speaks during a press conference to present the 2023 annual results of LVMH in Paris, France, January 25, 2024. LVMH shares jumped more than 8% on Friday morning, after the world's largest luxury group posted higher-than-expected sales for 2023 and raised its annual dividend. The result was boosted in particular by 14% annual growth in the critical fashion and leather goods sector, along with 11% growth in perfumes and cosmetics. After a boom during the pandemic, the luxury sector endured a rough end to 2023 as challenging geopolitical and macroeconomic conditions weighed on consumer spending, particularly in the U.S. and China. Javier Gonzalez Lastra, portfolio manager of the Tema Luxury ETF, told CNBC on Thursday that investors are trying to gauge where the bottom of the earnings cycle revision is for the luxury sector.

Persons: Bernard Arnault, LVMH Moet Hennessy Louis Vuitton, LVMH, Louis Vuitton, Hennessy, Bulgari, Javier Gonzalez Lastra Organizations: LVMH, Chandon, Givenchy, Novo Nordisk, Burberry, CNBC, Paris Locations: Paris, France, U.S, China, LVMH, Tema

☆ How Eli Lilly plans to fix the supply snag for its blockbuster diabetes drug
▼ + stars: | 2024-01-26 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +8 min

They're also at the heart of our investment thesis in Eli Lilly, a longtime Club holding. Shares of Eli Lilly have soared nearly 80% over the past 12 months, including a more-than-5% gain in January alone. In November, Eli Lilly indicated it was on track to meet the goal, which also was made possible by upgrades to existing facilities. Eli Lilly has used KwikPen technology for other diabetes treatments, such as insulin injections, for many years. Eli Lilly & Co. Mounjaro brand tirzepatide medication arranged at a pharmacy in Provo, Utah, US, on Monday, Nov. 27, 2023.

Persons: Eli Lilly, —, Eli Lilly's, They're, FactSet, Lilly's, Dave Ricks, Ricks, Lilly, there's, Morgan Stanley, Eli, Jim Cramer's, Jim Cramer, Jim, George Frey Organizations: CNBC, FDA, Novo Nordisk, JPMorgan Healthcare Conference, Research, Barclays, RTP, —, U.S, JPMorgan, Bloomberg, Getty Locations: Danish, Indianapolis, North Carolina, Carolina, Concord , North Carolina, Germany, U.S, Australia, Canada, KwikPen, Provo , Utah

☆ Merck, Johnson & Johnson CEOs agree to testify in Senate hearing on high drug prices
▼ + stars: | 2024-01-26 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Sen. Bernie Sanders, I-Vt., holds his news conference with Sen. Ed Markey, D-Mass., in the Capitol on Thursday, January 25, 2024, on issuing subpoenas for pharmaceutical company CEOs to testify regarding drug prices. The CEOs of Merck and Johnson & Johnson have voluntarily agreed to testify at an upcoming Senate hearing on high drug prices in the U.S., Sen. Bernie Sanders announced Friday, as lawmakers ramp up efforts to rein in health-care costs for Americans. Meanwhile, Bristol Myers Squibb CEO Chris Boerner and another unnamed pharmaceutical CEO agreed to initial invitations to testify. The push to cut drug prices is one of the rare issues that has united both major political parties in recent years — though they have often backed different approaches to doing so. Last year, the Senate Health Committee similarly heard testimony from the CEOs of Moderna , Eli Lilly , Novo Nordisk and Sanofi on high drug prices.

Persons: Sen, Bernie Sanders, Ed Markey, Johnson, Joaquin Duato, Robert Davis, Chris Boerner, Sanders, Januvia, Bristol Myers, Joe Biden's, J, Eli Lilly Organizations: Merck, Johnson, Health, Education, Labor, Pensions, Bristol Myers, Bristol, J, Moderna, Novo Nordisk, Sanofi Locations: U.S

☆ Eli Lilly's Zepbound is off to a strong start, but here's what needs to happen to push shares higher
▼ + stars: | 2024-01-24 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +8 min

Lilly's Mounjaro and Zepbound both use tirzepatide as an active ingredient, but Mounjaro is indicated for type 2 diabetes, while Zepbound aids weight loss. A rich valuation LLY 1Y mountain Eli Lilly shares over the past year. But even good news about Zepbound's launch might not be enough to propel Lilly's stock higher. Goldman's Shibutani has a neutral rating on Lilly shares and a price targe of $600, which implies shares could fall nearly 5% from they started the week. He has a buy rating on Lilly shares, and expects the stock could hit $700 over the next 12 months.

Persons: Eli Lilly's, Lilly, Goldman Sachs, Chris Shibutani, IQVIA, Shibutani, Lilly's, Mounjaro, Eli Lilly, Geoff Meacham, NASH, Meacham, there's, Morgan Stanley, Terence Flynn, Flynn, Morgan Stanley's, Michael Bloom Organizations: Food and Drug Administration, Zepbound, Novo Nordisk's, Medicare, Bank of America, Novo Nordisk, Bank of, FDA, CNBC Locations: Indianapolis, Mounjaro

☆ Bernard Arnault, the world's 3rd-richest person, is set to appoint 2 more of his children to the LVMH board
▼ + stars: | 2024-01-23 | by ( Grace Dean | ) www.businessinsider.com time to read: +3 min

Read previewBernard Arnault, the world's third-richest person, is set to appoint two more of his children to LVMH's board, France's La Lettre first reported. The French billionaire plans to propose his sons Alexandre Arnault, 31, and Frédéric Arnault, 29, as board members, the reports say, quoting unnamed sources. Four of Arnault's five children will sit on the LVMH board if their appointments are confirmed. Arnault cofounded LVMH in the 1980s and is its CEO and chairman. In May 2023, he became the third person to be worth more than $200 billion, according to the Bloomberg Billionaires Index.

Persons: —, Bernard Arnault, France's, Alexandre Arnault, Frédéric Arnault, Delphine, Bernard's, Antoine, It's, Arnault hasn't, LVMH, Alexandre, Vianney Le Caer, Louis Vuitton, Dior, Marc Jacobs, LVMH didn't, Donald Trump, he'd, Frédéric, Delphie, Dior Couture, Jean, Louis Vuitton's, Arnault, Elon Musk, Jeff Bezos Organizations: Service, Bloomberg, The Financial Times, Business, Novo Nordisk, Tiffany, New York Times, Mar, TAG, Christian Dior, Elon Locations: French, Danish, Swiss, LVMH

☆ Missed the Novo and Lilly rally? These 4 under-the-radar anti-obesity drug stocks could soar, Berenberg says – giving one 44% upside
▼ + stars: | 2024-01-22 | by ( Ganesh Rao | ) www.cnbc.com time to read: +2 min

The anti-obesity drug market is expected to remain in focus this year after a bumper 2023 for weight loss drugmakers Novo Nordisk and Eli Lilly , according to Berenberg. GLP-1 drugs encourage the production of hormones that cause weight loss through reduced appetite. Nevertheless, Berenberg's analysts believe the bigger, underappreciated, near-term opportunity lies with companies preparing to launch generic versions of the first-generation GLP-1 drugs. Under-the-radar picks Sartorius and SKAN Group, Berenberg's "under-the-radar" pick, are also expected to benefit from manufacturing generic GLP-1 drugs. The investment bank sees Sartorius benefiting from the growing commercialization of GLP-1 drugs and forecasts shares to rise by 27% over the next 12 months.

Persons: Eli Lilly, Novo, Sandoz, Berenberg Organizations: Novo Nordisk, —, Nordisk, Novo Nordisk's Victoza, SKAN Locations: Germany, Europe, Sandoz, United States

☆ Morgan Stanley likes biopharma as a defensive play — giving one stock 119% upside
▼ + stars: | 2024-01-22 | by ( Ganesh Rao | ) www.cnbc.com time to read: +3 min

The biopharmaceutical sector is expected to offer a safe haven from macroeconomic and earnings concerns ahead of final quarterly results from companies, according to Morgan Stanley. Morgan Stanley, however, cautioned that the outlook for drug pricing reform in the U.S. poses risks for the sector. Shares of Indivior , argenx , AstraZeneca , Merck , Lonza, Sweden's Sobi, Novo Nordisk and Sandoz Group were among those listed by Morgan Stanley with a "buy" rating. In a bull case where Sublocade hits $2.2 billion in sales by 2030, Morgan Stanley sees shares rising further to 3,500 British pence. Novo Nordisk Shares of Novo Nordisk , a leader in diabetes and obesity drugs, offer a 9.4% upside, according to Morgan Stanley.

Persons: Morgan Stanley, Mark D Purcell, Sweden's, Sublocade, Thibault Boutherin, Morgan, — CNBC's Michael Bloom Organizations: Barclays, Bank of America, AstraZeneca, Merck, Lonza, Novo Nordisk, Sandoz Group, AstraZeneca AstraZeneca, British pharma, EU Locations: U.S, argenx, Novo, Indivior

Search resuls for: "nordisk"

25 mentions found